These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 29687281)

  • 1. Prognostic value of Ki-67 index in adult medulloblastoma after accounting for molecular subgroup: a retrospective clinical and molecular analysis.
    Zhao F; Zhang J; Li P; Zhou Q; Zhang S; Zhao C; Wang B; Yang Z; Li C; Liu P
    J Neurooncol; 2018 Sep; 139(2):333-340. PubMed ID: 29687281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular subgroups of adult medulloblastoma: a long-term single-institution study.
    Zhao F; Ohgaki H; Xu L; Giangaspero F; Li C; Li P; Yang Z; Wang B; Wang X; Wang Z; Ai L; Zhang J; Luo L; Liu P
    Neuro Oncol; 2016 Jul; 18(7):982-90. PubMed ID: 27106407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
    Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
    PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical treatment and outcome of cerebellopontine angle medulloblastoma: a retrospective study of 15 cases.
    Wu T; Qu PR; Zhang S; Li SW; Zhang J; Wang B; Liu P; Li CD; Zhao F
    Sci Rep; 2020 Jun; 10(1):9769. PubMed ID: 32555264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.
    Łastowska M; Trubicka J; Niemira M; Paczkowska-Abdulsalam M; Karkucińska-Więckowska A; Kaleta M; Drogosiewicz M; Perek-Polnik M; Krętowski A; Cukrowska B; Grajkowska W; Dembowska-Bagińska B; Matyja E
    J Neurooncol; 2018 Jun; 138(2):231-240. PubMed ID: 29427151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
    Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
    J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of pathologic characteristics and prognosis in different subtypes of adult medulloblastoma].
    Zhao F; Zhang J; Wang X; Wang Z; Wang Y; Qu P; Luo L; Liu P
    Zhonghua Bing Li Xue Za Zhi; 2014 Mar; 43(3):169-72. PubMed ID: 24842015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histologic Correlates of Molecular Group 4 Pediatric Medulloblastoma: A Retrospective Canadian Review.
    Triscott J; Yip S; Johnston D; Michaud J; Rassekh SR; Hukin J; Dunn S; Dunham C
    Pediatr Dev Pathol; 2021; 24(4):309-317. PubMed ID: 33749384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomic profiling of medulloblastoma reveals novel proteins differentially expressed within each molecular subgroup.
    Narayan V; Jaiswal J; Sugur H; Sd S; Rao S; Chatterjee A; Gowda H; A A; Somanna S; Santosh V
    Clin Neurol Neurosurg; 2020 Sep; 196():106028. PubMed ID: 32580068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical expression of markers Ki-67, neun, synaptophysin, p53 and HER2 in medulloblastoma and its correlation with clinicopathological parameters.
    Meurer RT; Martins DT; Hilbig A; Ribeiro Mde C; Roehe AV; Barbosa-Coutinho LM; Fernandes Mda C
    Arq Neuropsiquiatr; 2008 Jun; 66(2B):385-90. PubMed ID: 18641877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological characteristics, molecular subgrouping, and expression of miR-379/miR-656 cluster (C14MC) in adult medulloblastomas.
    Kaur K; Kakkar A; Kumar A; Purkait S; Mallick S; Suri V; Sharma MC; Julka PK; Gupta D; Suri A; Sarkar C
    J Neurooncol; 2016 Dec; 130(3):423-430. PubMed ID: 27576698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.
    Park AK; Lee JY; Cheong H; Ramaswamy V; Park SH; Kool M; Phi JH; Choi SA; Cavalli F; Taylor MD; Kim SK
    BMC Cancer; 2019 Jun; 19(1):571. PubMed ID: 31185958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas.
    Korshunov A; Sahm F; Zheludkova O; Golanov A; Stichel D; Schrimpf D; Ryzhova M; Potapov A; Habel A; Meyer J; Lichter P; Jones DTW; von Deimling A; Pfister SM; Kool M
    Neuro Oncol; 2019 Feb; 21(2):214-221. PubMed ID: 30252101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinicobiological model predicting survival in medulloblastoma.
    Ray A; Ho M; Ma J; Parkes RK; Mainprize TG; Ueda S; McLaughlin J; Bouffet E; Rutka JT; Hawkins CE
    Clin Cancer Res; 2004 Nov; 10(22):7613-20. PubMed ID: 15569993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subgroup and subtype-specific outcomes in adult medulloblastoma.
    Coltin H; Sundaresan L; Smith KS; Skowron P; Massimi L; Eberhart CG; Schreck KC; Gupta N; Weiss WA; Tirapelli D; Carlotti C; Li KKW; Ryzhova M; Golanov A; Zheludkova O; Absalyamova O; Okonechnikov K; Stichel D; von Deimling A; Giannini C; Raskin S; Van Meir EG; Chan JA; Fults D; Chambless LB; Kim SK; Vasiljevic A; Faure-Conter C; Vibhakar R; Jung S; Leary S; Mora J; McLendon RE; Pollack IF; Hauser P; Grajkowska WA; Rubin JB; van Veelen MC; French PJ; Kros JM; Liau LM; Pfister SM; Kool M; Kijima N; Taylor MD; Packer RJ; Northcott PA; Korshunov A; Ramaswamy V
    Acta Neuropathol; 2021 Nov; 142(5):859-871. PubMed ID: 34409497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histological variants of medulloblastoma are the most powerful clinical prognostic indicators.
    Massimino M; Antonelli M; Gandola L; Miceli R; Pollo B; Biassoni V; Schiavello E; Buttarelli FR; Spreafico F; Collini P; Giangaspero F
    Pediatr Blood Cancer; 2013 Feb; 60(2):210-6. PubMed ID: 22693015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DJ-1 is activated in medulloblastoma and is associated with cell proliferation and differentiation.
    Lin JP; Pan BC; Li B; Li Y; Tian XY; Li Z
    World J Surg Oncol; 2014 Dec; 12():373. PubMed ID: 25475127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes.
    Korshunov A; Okonechnikov K; Schrimpf D; Tonn S; Mynarek M; Koster J; Sievers P; Milde T; Sahm F; Jones DTW; von Deimling A; Pfister SM; Kool M
    Acta Neuropathol; 2023 Jun; 145(6):829-842. PubMed ID: 37093271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. M1 macrophage recruitment correlates with worse outcome in SHH Medulloblastomas.
    Lee C; Lee J; Choi SA; Kim SK; Wang KC; Park SH; Kim SH; Lee JY; Phi JH
    BMC Cancer; 2018 May; 18(1):535. PubMed ID: 29739450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.